Jolkinolide A

立即咨询

Jolkinolide A

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

37905-07-0

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

Jolkinolide A 是一种二萜类化合物，可从大戟属植物 (Euphorbia fischeriana Steud) 的根中提取。Jolkinolide A 具有抗肿瘤活性，通过影响肿瘤组织的血管生成。Jolkinolide A 可显著抑制Akt-STAT3-mTOR信号通路，降低VEGF在 A549 细胞中的表达。

生物活性

Jolkinolide A is a diterpenoid, can be extracted from the roots ofEuphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits theAkt-STAT3-mTORsignaling pathway and reduces the expression ofVEGFin A549 cells^[1].

IC₅₀& Target

VEGF^[1]

体外研究
(In Vitro)

Jolkinolide A (20-100 μg/mL; 24 h) 提高 A549 细胞中 caspase-9 蛋白水平^[1]。
Jolkinolide A (40-80 μg/mL; 24 h) 降低 A549 细胞中 Akt-STAT3-mTOR 蛋白的表达^[1]。
Jolkinolide A (20-100 μg/mL; 24 h) 抑制人脐静脉内皮细胞 (HUVEC) 增殖和迁移，促进细胞凋亡^[1]。

Western Blot Analysis^[1]

Cell Line:	A549 cells
Concentration:	20 μg/mL, 40 μg/mL, 60 μg/mL, 80 μg/mL, and 100 μg/mL
Incubation Time:	24 hours
Result:	Promoted caspase-9 protein expression in cells at 20-100 μg/mL. Inhibited expression levels of Akt, STAT3, and mTOR proteins in cells at 40-80 μg/mL.

体内研究
(In Vivo)

Jolkinolide A (40 mg/kg; 腹腔注射; 每 3 天一次，持续 2 个月) 抑制小鼠A549细胞异种移植瘤模型中VEGF蛋白的表达^[1]。

Animal Model:	Female BALB/c nude mice (4-5 weeks old) injected with A549 cells^[1]
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once every 3 days for 2 months
Result:	Significantly inhibited the expression of VEGF protein on the first, 10th, 30th, 45th, and 60th day of administration.

分子量

314.42

Formula

C₂₀H₂₆O₃

CAS 号

37905-07-0

结构分类

Terpenoids
Diterpenoids

来源

Plants
Euphorbiaceae
Euphorbia fischerianaSteud.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.